Atossa Therapeutics (ATOS) vs Quoin Pharmaceuticals (QNRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Quoin Pharmaceuticals (QNRX) has outperformed Atossa Therapeutics (ATOS) over the past year, losing 44.9% versus a loss of 85.5%. Over five years, ATOS leads with a -94.4% price change compared with -100.0% for QNRX. Atossa Therapeutics is the larger company by market cap ($24.3 million vs $21.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATOS | QNRX |
|---|---|---|
| Share price | $2.44 | $4.50 |
| Market cap | $24.35M | $21.62M |
| 1-day change | +0.83% | -1.10% |
| YTD return | -72.66% | -68.81% |
| 1-year return | -85.47% | -44.85% |
| 5-year return | -94.36% | -99.99% |
| EPS (TTM) | $-4.45 | $-5.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.00 | $41.80 |
| 52-week low | $1.70 | $3.25 |
| Distance from 52-week high | -86.44% | -89.23% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +678.69% | +385.11% |
| Average volume | 63.48K | 541.11K |
| Shares outstanding | 9.98M | 4.80M |
| Employees | 16 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QNRX has outperformed ATOS by 40.6 percentage points over the past year.
About Atossa Therapeutics
ATOS stock →Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Quoin Pharmaceuticals
QNRX stock →Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
ATOS vs QNRX FAQ
Which is bigger, Atossa Therapeutics or Quoin Pharmaceuticals?
Atossa Therapeutics (ATOS) is larger, with a market capitalization of $24.35M compared with $21.62M for Quoin Pharmaceuticals (QNRX).
Which stock has performed better over the past year, ATOS or QNRX?
QNRX returned -44.85% over the past 12 months, compared with -85.47% for ATOS (price return, excluding dividends). Past performance does not predict future results.
Are Atossa Therapeutics and Quoin Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.